Tag: Olympus

Olympus’s Net-Zero Targets Approved by SBTi

  • Olympus aims to achieve net-zero greenhouse gas emissions throughout the entire supply chain by 2040

Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, today announced that the Science Based Targets initiative(SBTi)[1] has verified Olympus’s net-zero[2] science-based target by 2040. The net-zero target, which was included in the Company Strategy announced in May 2023, is to achieve net-zero greenhouse gas emissions (Scope 1, 2, and 3[3]) for the entire supply chain by 2040 and was certified as a goal consistent with the 1.5 degrees Celsius increase limit target defined by the Paris Agreement. It also included a near-term target to reduce absolute Scope 1 and 2 GHG emissions 70% by FY2031. 

Olympus strongly believes that climate change and ecosystem deterioration, brought about by human activities impacting the environment and pollution, must be addressed promptly. In May 2021, the company added “carbon neutral society and circular economy” to its materiality items. In addition, in May 2023, it formulated and announced a target of achieving net-zero greenhouse gas emissions throughout the entire supply chain (Scope 1, 2, and 3) by 2040 in order to contribute broadly to the realization of a decarbonized society. Now, Olympus’ near-term target and net-zero target have acquired certification from SBTi as goals consistent with the target 1.5 degrees Celsius increase limit outlined by the Paris Agreement.

Olympus’ net-zero target
Olympus commits to reach net-zero GHG emissions across the value chain by 2040.

Olympus’ near-term targets
Olympus commits to reduce absolute scope 1 and 2 GHG emissions 70% by FY2031 from a FY2020 base year.

Olympus also commits that 80% of its suppliers by emissions covering purchased goods and service, capital goods, and upstream transportation and distribution will have science-based targets by FY2028.

Comment from Yasuo Takeuchi, Olympus Director, Representative Executive Officer, and Executive Chairman and ESG Officer:
“Olympus has incorporated the concept of ESG into our corporate strategy toward the realization of Our Purpose of “making people’s lives healthier, safer and more fulfilling” and is actively developing various initiatives. The results of our efforts to date include a 45.7% reduction in greenhouse gas emissions in FY2023 compared to FY2020 and a 71.9% introduction rate of electricity derived from renewable energy. We recognize that this progress acknowledges our efforts towards setting and working to achieve our targets. We will continue to improve manufacturing, promote energy saving and introduce renewable energy at Olympus sites globally while implementing measures to develop environmentally-conscious products, improve logistics efficiency, set voluntary reduction targets in cooperation with suppliers, and support decarbonization initiatives.”

Comment from Luiz Amaral, Chief Executive Officer of the Science Based Targets initiative:
“Climate science tells us that we need rapid and deep emissions cuts if we are to achieve global net-zero and prevent the most damaging effects of climate change. Olympus Corporation’s net-zero targets match the urgency of the climate crisis and set a clear example that their peers must follow.”

[1]: An international initiative jointly established by WWF, CDP, the World Resources Institute (WRI), and the UN Global Compact. They encourage companies to set science-based greenhouse gas reduction targets in order to limit the increase in the average global temperature due to climate change to 1.5 degrees Celsius above pre-industrial levels.
[2]: Net-zero means reducing greenhouse gas emissions (Scope 1, 2, and 3) as much as possible (at least 90%) in line with the latest climate science (1.5°C scenario) and using credits derived from carbon sequestration and removal (such as afforestation and CO2 capture and storage) for an amount equivalent to the residual greenhouse gas emissions (less than 10%) to achieve a balance.
[3]: Scope 1: Direct greenhouse gas emissions by combustion of fuels in our sites.
Scope 2: Indirect greenhouse gas emissions from our sites use of electricity, heat or steam supplied by other companies.
Scope 3: Other, indirect emissions of greenhouse gas emissions (excluding Scope 1 and 2).

ESG Initiatives
For more information on Olympus’ ESG initiatives, please refer to the Sustainability page on its website.

About Olympus
At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global X account: @Olympus_Corp.

Media contact:
Airi Yuasa
Tel: +81-70-3923-6064
Mail: Global-Public_Relations@olympus.com

Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com 

Olympus to Launch Development Support Project in Kenya for the Diagnosis of Gastrointestinal Diseases

Selected by the National Center for Global Health and Medicine under the Ministry of Health, Labour and Welfare, Japan as “Projects for Global Growth of Medical Technologies, in 2023”

Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, today announced the launch of the “Kenya Endoscopy Human Resource Development Support Project for the Diagnosis of Gastrointestinal Diseases” to promote endoscopic care in Kenya, where there is a shortage of endoscopists. This program is funded by “Projects for Global Growth of Medical Technologies, in 2023” conducted by the National Center for Global Health and Medicine under the Ministry of Health, Labour and Welfare, Japan.

Olympus will conduct this project from July 2023 to January 2024 at Kenyatta National Hospital, a leading medical education institution in Kenya, in addition to other major medical institutions, including seven that received the latest endoscopic equipment provided by the Japanese Official Development Assistance (ODA) last year. Japanese physicians affiliated with the partner institutions will serve as lecturers and both train Kenyan doctors directly and instruct on how to train the next generation of endoscopists.

At the kick-off meeting on July 14, Elly O. Ogutu, M.D. from Nairobi Gastroenterology Training Centre, Kenyatta National Hospital said, “There is an increase of cancer cases in Kenya. It is my sincere hope that the project will be a great success and expand in the future to incorporate more areas in gastroenterology needing endoscopy services.” Dr. Tomohiko Moriyama, Director of Telemedicine Development Center of Asia, International Medical Department, Kyushu University, also commented, “It is our hope that, through this project, Japan and Kenya will share knowledge and experience in the field of digestive system diseases, and thereby improve the level of medical care in each other’s countries and further deepen the friendship between the two countries.”

Background of Olympus’ Participation
In Kenya, the proportion of non-communicable diseases as a cause of death has been growing. Cancer is now the third-highest leading cause of death in the country, and esophageal, colorectal, and gastric cancers are the leading causes of gastrointestinal-related morbidity and mortality cases. In response to this social problem, the Kenyan Ministry of Health established a basic policy against cancer in 2019 and is currently strengthening its efforts by setting target screening figures for colorectal cancer for citizens aged 45 and older. However, while the demand for endoscopic screenings, which are essential for the early detection and treatment of cancer, is expected to increase, there is a shortage of physicians with the advanced knowledge and skills required for these examinations. Furthermore, there is a need to improve the standard of endoscopic care by enhancing the knowledge and skills of physicians. Olympus applied to be part of the Japanese government’s “Projects for Global Growth of Medical Technologies, in 2023” to contribute to the early detection and treatment of gastrointestinal cancers. This includes the international deployment of Japan’s latest medical technology through the training of Kenyan doctors, as well as helping to solve Kenya’s medical issues and assisting in the development of medical care.

Purpose of the Projects for Global Growth of Medical Technologies
The project aims to share knowledge and experience from Japan’s medical system and to promote the international deployment of Japanese medical products and technologies that are of high quality and meet the needs of partner countries. The purpose is also to contribute to the improvement of public health and medical standards in the partner country, to enhance the trust of Japan in the international community, and to bring about a virtuous circle for both Japan and the partner country.
Project Scope of “Kenya Endoscopy Human Resource Development Support Project for the Diagnosis of Gastrointestinal Diseases”

1) Educational activities on gastrointestinal endoscopy, which is indispensable for improving the level of medical care for gastrointestinal diseases in Kenya, will be conducted in cooperation with the International Medical Department of Japan’s Kyushu University Hospital, which has extensive experience in on-site training, training in Japan, and online training for healthcare professionals in emerging countries. The training will mainly be for medical personnel in Nairobi and surrounding counties where Japanese endoscopy equipment has been installed with the ODA. Training activities will be conducted jointly by industry and academia.
2) Training will be provided by Japanese lecturers in the areas of standard endoscopic screening and treatment of the upper and lower gastrointestinal tracts through classroom lectures, clinical guidance, and hands-on training using practical models. This will be a combination of on-site training, training in Japan, and online training. Olympus will arrange training courses and the equipment necessary for the training.

About Olympus
At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued the goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global Twitter account: @Olympus_Corp.

Media Contact:
Airi Yuasa
+81-70-3923-6064
Global-Public_Relations@olympus.com

Olympus to Acquire Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd

  • Strengthening Gastrointestinal Endotherapy Offerings Through Bringing Together Talent and Technology

Olympus Corporation (Olympus), a global medtech company committed to making people’s lives healthier, safer and more fulfilling, has agreed to acquire Taewoong Medical Co., Ltd, (Taewoong Medical), a Korea-based manufacturer of medical devices such as gastrointestinal (GI) metallic stents[1] to strengthen its GI endotheraphy product portfolio capabilities, and in turn, contributing to improving patient outcome through comprehensive solutions.

Taewoong Medical
Niti-S Hot SPAXUS(TM) Stent & Electrocautery Stent Delivery System

Taewoong will receive approximately $370 million in cash, of which $255.5 million will be paid at the closing and up to $114.5 million will be paid if future milestones is achieved. The company expects to complete the transaction on June 30, 2023, subject to customary closing conditions.

Incidences of biliary cancers, where metallic stents are frequently used as one of the treatments, have been increasing in recent years[2] due to the aging population[3]. Metallic stents are often used to treat jaundice, one of the symptoms of an obstructed or narrowed biliary tract caused by biliary cancer. The stent allows for minimally invasive treatment[4], which supports faster patient recovery.

Different types of stents are needed depending on the condition of the lesion and the patient’s anatomy. Taewoong Medical, a leading manufacturer of GI stents, offers a variety of medical devices including metallic stents designed for biliary tract, esophagus, colon, and duodenum treatments[5]. GI stents are used to help clear occlusions or strictures by cancer or other diseases. Moreover, Taewoong Medical’s metallic stents combine strong radial force with high flexibility[6], which are both crucial requirements. This allows the stents to conform to the shape of anatomies such as biliary tracts and the esophagus, and even if curved, it is less likely for the stent to buckle, which reduces the risk of restenosis. Taewoong Medical has a wide range of high-quality stents realized through its unique design and technology capabilities, allowing healthcare professionals to use minimally invasive treatment with the most appropriate equipment for each patient.

Olympus is targeting GI as one of its key disease states, as outlined in its medical business strategy announced in December 2021. The addition of Taewoong Medical’s medical devices to its product portfolio will enable Olympus to become a comprehensive solutions provider in the GI market with varied solutions in GI, contributing to improved patient outcomes and elevating the standard of care.

“Olympus’ Endotherapy Division is committed to providing a full portfolio of clinically differentiated technologies aimed at treating patients who suffer from GI disease, and with the acquisition of Taewoong Medical, this further demonstrates our commitment to this critical segment of our business,” said Gabriela Kaynor, Global Division Head of Therapeutic Solutions Division at Olympus. “Taewoong Medical has developed a full portfolio of GI metal stents that will immediately enhance our already robust offering of GI devices. I’m proud to welcome Taewoong Medical’s employees, and their commitment to the field of GI endoscopy to the Olympus’ Therapeutic Solutions Division.”

Kyong-min Shin, President and CEO of Taewoong Medical stated, “For over three decades, Taewoong Medical has been a leading manufacturer of GI stents, renowned for its innovative technology and diverse product range. Our company has a robust market presence in Korea, Japan, and Europe, and exports to 86 countries worldwide. Moving forward together with Olympus, Taewoong Medical will focus its capabilities to provide medical professionals and patients with superior products and services through continuous investment in R&D and manufacturing technology.”

Moving forward, Olympus will continue to find and execute investments as well as expand its product and technology strengths through synergies with the products and technologies of acquired companies, ensuring that they capture maximum value through these integrations.

Overview of Taewoong Medical (as of Dec. 2022)
– Company name: Taewoong Medical Co., Ltd,
– Address: Gimpo-si, South Korea
– Established: 1992
– President and CEO: Kyong-min Shin
– Revenue: 6,790 million JPY[7] (as of Dec. 2021)
– Operating income: 1,347 million JPY[7] (as of Dec. 2021)
– Business: R&D and manufacturing of non-vascular metallic stents.
– Number of employees: 273
– Manufacturing: Gimpo-si, South Korea
– International footprint: Taewoong Medical currently sells in more than 80 geographies.

[1] A medical device made of a metallic mesh tube that is placed for dilating a stenosis within a tract such as biliary, esophagus, colon and duodenum.
[2] Guoqing Ouyang MM et al., “The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study 2017”
[3] https://ourworldindata.org/grapher/historic-and-un-pop-projections-by-age
[4] Jin-Seok Park, Seok Jeon, Don Haeng Lee “Recent Advances in Gastrointestinal Stent Development”
[5] Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.
[6] Isayama H, Nakai Y, Hamada T, et al.: Understanding the Mechanical forces of Self-Expandable Metal Stents in the Biliary Ducts. Curr Gastroenterol Rep 18 : 64, 2016.
[7] Calculated at the exchange rate of JPY 10.61 per 100 KRW (exchange rate as of the end of January 2023).

About Taewoong Medical
For over thirty years, Taewoong Medical has been dedicated to advancing medical technology and improving patient quality of life through the production and delivery of high-quality and innovative minimally invasive medical devices. Our flagship product, the Niti-S(TM) gastrointestinal stent, has been widely recognized as a pioneering and innovative solution, fulfilling the diverse needs of healthcare professionals globally. As our business continues to grow, we are expanding into new areas such as endoscopic instruments, interventional radiology and neurology devices, and pulmonary valves, with the aim of further improving patient outcomes. For more information, visit www.taewoongmedical.com.

About Olympus
As a leading medical technology company, our medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus’ medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, customer solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.

Media contact:
Global-Public_Relations@olympus.com

Olympus Corp [TYO: 7733] [ADR: OCPNY] [GDR: OLYS] https://www.olympus-global.com

Olympus Named to Dow Jones Sustainability World Index for Two Consecutive Years

Olympus Corporation (Olympus), a global medtech company committed to making people’s lives healthier, safer and more fulfilling, announced that it has been selected for inclusion in the 2022 Dow Jones Sustainability World Index (DJSI World) and the 2022 Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), both among the most globally recognized corporate sustainability indices. Olympus has been named to the DJSI World for two consecutive years and DJSI Asia Pacific for four.

The Dow Jones Sustainability Indices (DJSI) are corporate sustainability evaluation indices for environmental, social, and governance (ESG) investment. Jointly developed by S&P Dow Jones Indices and RobecoSAM, the DJSI track the financial performances of leading companies according to ESG criteria. These indices are updated annually to include companies with excellent corporate sustainability practices.

In 2022, 332 companies were selected as DJSI World members from approximately 3,500 companies worldwide in 61 industry sectors, and 156 companies were selected as DJSI Asia Pacific members from approximately 600 companies assessed in the region. Olympus is one of only 8 out of 64 companies to have been included in the DJSI World Health Care Equipment & Supplies sector. The company’s scores on Access to Healthcare, Talent Attraction & Retention, Tax Strategy, Environmental Policy & Management Systems were of particular note, being not only highly rated, but having also been improved over last year’s scores. In addition to the DJSI World and Asia Pacific, Olympus was also named to the FTSE4Good Index Series and FTSE Blossom Japan Index.

Stefan Kaufmann; Director, Executive Officer, and Chief Administrative Officer of Olympus, stated: “It is a great honor for Olympus to again be selected for the DJSI World and Asia Pacific. In order to realize Our Purpose of Making people’s lives healthier, safer and more fulfilling, we have taken various initiatives to contribute to society, positioning ESG as one of the most important strategic pillars in our Corporate Strategy. We are proud to be included in the DJSI World and Asia Pacific for consecutive years as evidence of our continuous evolution as well as our high reputation in ESG from stakeholders. We will further accelerate our efforts to realize a sustainable society.”

Based on Our Purpose, Olympus believes that the sustainability of a company will be recognized primarily by meeting the demands and expectations of society and fulfilling responsibilities through dialogue with all stakeholders. The company will continue to contribute to creating a sustainable society by actively engaging in activities that incorporate ESG perspectives to fulfill its corporate social responsibilities on a global scale.

For more information on Olympus’ ESG initiatives, please refer to its Integrated Report 2022[1] and the Sustainability page on its website[2].

[1] https://www.olympus-global.com/ir/data/integratedreport/2022.html?page=ir
[2] https://www.olympus-global.com/csr/

About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 30,000 employees worldwide in nearly 40 countries and regions. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp ( https://twitter.com/olympus_corp ).

Media contact:
Mieko Yamada
Global-Public_Relations@olympus.com

Olympus Corp [TYO: 7733] [ADR: OCPNY] [GDR: OLYS] https://www.olympus-global.com

Olympus to Join Government Project to Verify Dissemination of Endoscopic AI Diagnosis in Vietnam

Participating in the Ministry of Internal Affairs and Communications of Japan project to conduct a survey study for international expansion of AI diagnosis support system and education for doctors in Vietnam

Olympus Corporation (Olympus), a global medtech company committed to making people’s lives healthier, safer and more fulfilling, today announced their part in a project in cooperation with the Ministry of Internal Affairs and Communications of Japan (MIC), entitled, “Survey Study for International Expansion of Endoscopes Utilizing High-definition Imaging Technology AI Diagnosis Support System in Vietnam.”

This is the third year, after similar projects in Thailand in fiscal year 2021 and India in fiscal year 2020, that Olympus has acted as a corporate partner to investigate the effectiveness and potential dissemination of an AI diagnostic support system. As part of these projects, Olympus has researched clinical applications in collaboration with major local medical institutions. Past clinical use by doctors in India and Thailand, along with consultation with Japanese physicians, showed the effectiveness and potential for future use of EndoBRAIN-EYE and other endoscope diagnostic imaging support software.

From November 2022 to March 2023, Olympus, in collaboration with CYBERNET SYSTEMS CO., LTD., will conduct research on the effectiveness and future use of the AI diagnostic support system EndoBRAIN-EYE at Cho Ray Hospital and 108 Hospital in Vietnam. In addition, specialist lecturers and physicians from Japan’s Showa University Northern Yokohama Hospital and Shizuoka Cancer Center will provide expert guidance to doctors at major Vietnamese hospitals. They will train doctors in techniques for detecting diseases and differential diagnosis with colonoscopes using EndoBRAIN-EYE, and they will also instruct on how to train the next generation of endoscopists.

Participants in kick-off meeting
Participants in kick-off meeting

At the kick-off meeting on November 28, Ho Dang Quy Dung M.D. from Cho Ray Hospital said, “AI is a new and powerful technology making endoscpic procedure more efficient and high quality. I do think that AI will be the big breakthrough of the filed of GI endoscopy in the upcoming years. I hope we have the opportunity to work with Japanese experts in the field of AI in endoscopy.” Professor Shin’ei Kudo from Showa University Northern Yokohama Hospital also commented, “I hope this project will contribute to not only dissemination of the AI technology but also increased partnership between Vietnam and Japan, and look forward to amazing results from this exciting collaboration.”

Background of Olympus’ Participation
Cancer rates have been on the rise in recent years in Vietnam, and colorectal cancer in particular has become a significant issue. It ranks fourth among all cancer cases in men and third among all cancers in women, as well as ranking second in mortality rate among all cancers in both men and women. While the demand for endoscopic screenings, which are essential for the early detection and treatment of cancer, is expected to increase, there is a shortage of physicians with the advanced knowledge and skills required for these examinations. Olympus has joined this project to support the specialists training doctors in Vietnam, to verify the effectiveness and dissemination of AI-assisted colonoscopy, and to contribute to the development of the healthcare environment in Vietnam.

Purpose of the MIC Project
The MIC aims to realize the sustainable development goals and SDG pledges to ensure “no one will be left behind.” To this end, the MIC aims to realize a model that contributes to SDG through digitization and to disseminate and promote an SDG + ICT model domestically and overseas between both the public and private sectors. This project aims to contribute to the introduction and dissemination of Japan’s endoscopic AI diagnostic support system to Vietnam in response to the social issue of increasing cancer prevalence in Vietnam.

Project Scope:
1) Surveys on the policies in the medical, health, and hygiene sectors and the introduction of medical information and communication technology
Information will be collected from major medical institutions and external research institutions to investigate the state of dissemination of medical information systems, including endoscopy systems.

2) Verification through proof-of-concept tests
Research will be conducted on the effectiveness and future use of the AI diagnosis support system at Cho Ray Hospital and 108 Hospital in Vietnam. Physicians from Showa University Northern Yokohama Hospital and Shizuoka Cancer Center will train doctors at major Vietnamese hospitals covering processes from the detection of disease utilizing a colonoscope with an AI diagnostic support system to discriminatory diagnosis, as well as provide training in how to pass on this knowledge to other doctors. Olympus will provide equipment and training courses.

Company names and product names in this release are trademarks or registered trademarks of each company.
Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.

About Olympus
In its Endoscopic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance the quality of life for patients. Starting with the world’s first gastrocamera in 1950, Olympus’ Endoscopic Solutions portfolio has grown to include endoscopes, laparoscopes, and video imaging systems, digital and integrated customer solutions, as well as solutions for infection prevention. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.

Media contact:
Nao Tsukamoto
Global-Public_Relations@olympus.com

Olympus Corp [TYO: 7733] [ADR: OCPNY] [GDR: OLYS] https://www.olympus-global.com

Olympus Announces Launch of Olympus Asia Pacific Innovation Program

As part of Olympus‘ dedication to continuing its history of innovation, Olympus is proud to announce the inaugural Olympus Asia Pacific Innovation Program (OAIP).

Olympus Corporation (Olympus), a global medtech company committed to making people’s lives healthier, safer and more fulfilling, has partnered with MedTech Innovator Asia Pacific, the industry’s largest healthcare accelerator, to facilitate the OAIP running throughout 2023.

Over a century old, Olympus has a rich heritage in the field of medical device innovation, having made a substantial impact on lives, with a portfolio of solutions that provide treatment for approximately 100[1] diseases or conditions, including the top four[2] of five cancers by global incidence rates. Olympus believes that the emergence of new technologies, particularly those within the digital realm, will revolutionize the patient care paradigm. Patient outcomes will be improved by optimizing the care pathway for individual patients based on their unique needs.

Olympus invites visionary startups to contribute to this revolution by participating in the OAIP and submitting their technologies that play a meaningful role in the advancement of minimally invasive care and new ways to detect, monitor, and treat conditions and diseases. Shortlisted startups will be invited to pitch across various in-person and virtual pitch events in front of Olympus executives and leaders over two phases from May 2023 to September 2023, with the winning innovator receiving grant funding of $75,000 as well as an exclusive mentorship program with key thought leaders from within Olympus.

Felicia Chung, Olympus Business Development Leader for the Asia Pacific region said “I am pleased to announce Olympus’ first-ever Innovation Program that seeks to identify and collaborate with innovators in the very exciting medtech space. APAC is a hotbed of innovative and bold ideas, especially in the space of digital solutions, and we are excited to uncover promising technologies that positively impact human health and create tangible value for providers and patients. We look forward to kick-starting this program and to playing a meaningful role in the advancement of minimally invasive care by identifying new ways to detect, monitor, and treat conditions and diseases.”

Marc Radatt, CEO for Olympus Corporation of Asia Pacific Limited and board member of the Asia Pacific Medical Technology Association (APACMed), said “Olympus is proud to have partnered with MedTech Innovator Asia Pacific in pursuit of new ideas that will revolutionize patient outcomes and increase access to new technologies through the OAIP. Initiatives like these promote industry wide collaboration, and access to valuable funding and mentorships that result in meaningful change and facilitate greater medtech thought leadership across our region.”

To apply for the OAIP, please visit:
https://medtechinnovator.org/olympusapac2023/

Participation Criteria
Visionaries are invited to submit solutions that play a meaningful role in the advancement of minimally invasive care and new ways to detect, monitor, and treat conditions and diseases.

Of particular interest are technologies focused on cancers and diseases of the stomach, colon, and lungs, and within the urology specialty. Examples may include:

  • Smart endoscopy, enabling early detection and advanced endoluminal therapy/treatment
  • Robotics, sensing, monitoring, and navigation technology for future autonomy in minimally invasive diagnosis/surgery/treatment
  • Transformation of the patient care pathway from pre-surgery planning through post-surgical care, supported by, for example:
    • AI for clinical efficiency & predictive analysis
    • 3D/4D image reconstruction for surgical procedures
  • Novel device/procedural solutions that may replace current procedures or offer an alternative to drug treatments
  • Innovations that enable non- or less-invasive diagnosis, surgery, and treatment
  • Ethical AI / digitally enabled technologies
  • Next-generation automated documentation
  • Smart gastro clinics and remote patient monitoring related to gut health

Through the OAIP, Olympus aims to identify the next revolutionary solution that will help to elevate the standard of care for patients globally, in line with Olympus’ purpose of making people’s lives safer, healthier and more fulfilling.

About Olympus
As a leading medical technology company, Olympus’ Medical Business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, customer solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.

About MedTech Innovator
Based in Los Angeles, Calif., MedTech Innovator is the largest accelerator of medical device companies in the world and the premier startup accelerator in the medical technology industry. Its mission is to improve the lives of patients by accelerating the growth of companies that are transforming the health care system. MedTech Innovator matches health care industry leaders with innovative early stage and emerging-growth medtech companies for mentorship and support. To date, MedTech Innovator has supported 509 alumni that have gone on to raise $6 billion in follow-on funding, and brought more than 200 products to regulatory clearance or approval. For more information, visit MedTech Innovator and follow @MedTechAwards on Twitter and MedTech Innovator on LinkedIn. To receive industry insights and highlights about MedTech Innovator’s current and alumni participant companies, subscribe to its monthly newsletter.

[1] As of March 2022
[2] Lung, stomach, colon, and prostate cancers – the top four highest incidence of cancers excluding breast cancer, as of March 2022. Source: GLOBAL CAN 2020

Olympus Announces Leadership Succession Plan

  • Stefan Kaufmann tentatively appointed new Director, Representative Executive Officer, President and CEO as the global medtech leader prepares for the company’s next stage of growth

Olympus Corporation (Olympus), a global medtech company committed to making people’s lives healthier, safer and more fulfilling, today announced that Stefan Kaufmann, the current Director, Executive Officer and Chief Administrative Officer, has been tentatively appointed Director, Representative Executive Officer, President, and CEO of the company effective April 1, 2023. Yasuo Takeuchi, the current Director, Representative Executive Officer, President, and CEO will serve as Director, Representative Executive Officer, Chairman, and ESG Officer. These changes are scheduled to be formally decided by the Board of Directors at the end of March 2023.

Stefan Kaufmann tentatively appointed new Director, Representative Executive Officer, President and CEO as the global medtech leader prepares for the company’s next stage of growth

The leadership transition is intended to strengthen the company’s management foundation as Olympus executes its value-creation plan. Takeuchi has led Olympus’ recent transformation journey to become a leading global medtech company. Moving forward, Kaufmann will lead the company’s resources to elevate the standard of care in targeted diseases and pursue Our Purpose of “making people’s lives healthier, safer and more fulfilling” and accelerate its growth.

Yasuo Takeuchi: Celebrated Architect of Change
Takeuchi’s four-year tenure at the helm of Olympus saw the most extensive corporate reorganization in the company’s storied 103-year history. An Olympus veteran with more than four decades of experience with the company, Takeuchi oversaw the transfer of the company’s imaging and scientific solutions businesses and its renewed focus on medtech, with the introduction of a myriad of operational changes and structural reforms bringing improvements in efficiency, innovation, and customer care.

Key achievements include changing the governance structure into a nomination committee structure. This has resulted in an executive management structure consisting of fewer people, which has streamlined the internal decision-making process. Additionally, global governance structure has been strengthened by increasing management agility and enhancing diversity of Board of Directors. Takeuchi has expanded the global research and development network and has comprehensively managed the business on a global scale. He also spearheaded the company’s global business development through acquisitions and early-stage investments to stimulate next-generation innovation.

Despite the volatility of the global economic environment in recent years, Olympus has achieved strong financial results and managed to reach committed targets, and is on track to achieving over 20% consolidated corporate operating margin.

Takeuchi stated: “It has been a privilege to lead Olympus through a historic moment for the company. With the completion of the groundwork of transformation in the first three years since the corporate strategy was announced in 2019, we can now shift to the next phase to accelerate growth and improve performance. I have full confidence that Stefan will continue this momentum. He has been instrumental in implementing the Transform Olympus initiatives and in shaping the future direction of the company to expand our contribution to global healthcare and address unmet needs with gastrointestinal, urological, and respiratory care solutions. After more than 15 years of working closely with Stefan, I look forward to continuing our partnership and to supporting him as he leads Olympus to the next level of growth and organizational efficiency.”

Stefan Kaufmann: Enduring Focus on Growth and Impact
An Olympus veteran with two decades of experience in senior roles, Kaufmann has a background in human resources and a strong track record in driving transformational change for Olympus in the complex Europe, Middle East, and Africa region.

Kaufmann most recently served concurrently as Olympus’ Chief Administrative Officer, Chief Strategy Officer, and Chief Transformation Officer, with responsibility for overseeing the implementation of the Transform Olympus program.

“I am honored and humbled at the opportunity to serve as the next Director, Representative Executive Officer, President, and CEO of Olympus,” Kaufmann said. “After years of very successful transformation, we see further opportunities to advance our global operations and processes with a strong focus on elevating the standard of care to benefit our customers and patients. Looking three-to-five years ahead, our key themes will be innovation, research, and development and inorganic growth, competitive performance, talent development, and sustainability.”

From April 2023, Kaufmann will drive the continued expansion of Olympus in the medtech field and prioritize business excellence as the company adapts to changing clinical needs and stricter ESG requirements.

Olympus will retain its strong customer orientation under Kaufmann and will continue to increase innovation cycles through in-house research, acquisitions, investment, and co-creation with industry partners. One of his priorities is the development of the quality and regulatory function toward further maturity, which is critical in the medical industry. He will also focus on evolving the work culture and developing the talent base in both Japan and globally.

Newly Appointed Executive Officers
The composition of the Group Executive Committee (GEC) will be changed following the leadership transition. The roles of Chief Administrative Officer and Chief Operations Officer will be dissolved, while the business leadership of ESD and TSD, Chief Quality Officer, Chief Human Resources Officer, as well as the Chief Strategy Officer will join the GEC, bringing a greater diversity of views and industry best practices.

About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. In its Endoscopic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance the quality of life for patients. Starting with the world’s first gastrocamera in 1950, Olympus’ Endoscopic Solutions portfolio has grown to include endoscopes, laparoscopes, and video imaging systems, as well as customer solutions and medical services. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.

Contact
Nao Tsukamoto – Global-Public_Relations@olympus.com

Olympus Corp. [TYO: 7733] [ADR: OCPNY] [GDR: OLYS], https://www.olympus-global.com.

Olympus EU-ME3 Ultrasound Processor Delivers Higher Resolution Images for Endoscopic Ultrasound

~ To Support More Accurate Diagnosis and Treatment of Pancreaticobiliary and Lung Diseases ~

Olympus Corporation (Olympus), a global medtech company committed to making people’s lives healthier, safer and more fulfilling, today announced the launch of EU-ME3, a new Endoscopic Ultrasound Processor*, which addresses the needs of healthcare professionals for high-quality clear images when conducting the endoscopic ultrasound procedure. EU-ME3 will be launched in Europe, the Middle East, Africa, parts of Asia, and Oceania within this fiscal year. EU-ME3 will be exhibited during The 30th United European Gastroenterology Week (UEG Week) from October 8 to 11.  

Olympus announces the global launch of the EVIS EUS Endoscopic Ultrasound Center EU-ME3. [Image: Olympus Corp]

As a pioneer in endoscopic ultrasound technology, Olympus aims to leverage its expertise to enhance the care pathway in gastrointestinal and respiratory disease management. The technology is used for endoscopic ultrasonography (EUS) imaging to support the diagnosis of lesions in the pancreas, the bile ducts, or lesions that are located deep inside the body and are not visible with gastrointestinal endoscopes. In addition, the technology enhances the detailed examination of pancreatitis, pancreatic cancer, and the diagnosis of cancer invasion in the stomach and the esophagus. Endoscopic ultrasound also plays a key role in facilitating the visualization of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for early, minimally invasive diagnosis and lung cancer staging.

“It is said that pancreatic cancer is difficult to be detected in its early stages, and that lung cancer has the highest mortality rate among all cancers. With the launch of the EU-ME3, Olympus aims to enhance the standard of care including these diseases and to further improve the quality of life of patients,” said Hironobu Kawano, Head of Endoscopic Solutions Division at Olympus.

Advancing the dimensions of Endosonography
With the needs of healthcare professionals and patient outcomes at the core, EU-ME3 is tailored to improve a variety of procedures.

Enhanced visualization and usability
EU-ME3 provides outstanding image quality and functionality – the image quality has been substantially enhanced compared to the prior generation model (EU-ME2), providing enhanced visualization, and therefore supporting more reliable diagnosis and treatment. Shear Wave Quantification, a newly equipped feature for EU-ME3, also contributes to accurate diagnosis by providing quantitative information on the stiffness of tumor and inflamed lesions, which is an important factor when diagnosing a degree of pancreatitis and malignancy of pancreatic cancer during endoscopic ultrasonography.

Focus on the procedure with tailored technology
The Endoscopic ultrasound procedure typically utilizes a variety of observation modes dependent on procedure type or clinical area. Subsequently, in addition to the basic observation mode, EU-ME3 offers multiple software options for individual clinical needs, aiming to stay flexible in the selection of functions and tailor EU-ME3 depending on specialty. Smart and customizable user settings make it easy to fulfil needs for multiple specialties and personal requirements. The backlit keyboard includes a simple, easy-to-use large touch panel and trackpad, designed to support better operability and easier cleaning.

With EU-ME3, the aim is to provide seamless workflow integration for our partners while advancing the dimensions of endosonography for better overall patient outcome.

About Olympus
In its Endoscopic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance the quality of life for patients. Starting with the world’s first gastrocamera in 1950, Olympus’ Endoscopic Solutions portfolio has grown to include endoscopes, laparoscopes, and video imaging systems, digital and integrated customer solutions, as well as solutions for infection prevention. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.

Media Contacts
Nao Tsukamoto – Global-Public_Relations@olympus.com
Jessica Lee – Jessica.yy.lee@fleishman.com

* Registered name: EVIS EUS ENDOSCOPIC ULTRASOUND CENTER OLYMPUS EU-ME3. EU-ME3 is manufactured by Olympus Medical Systems Corporation.
* Note: Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.

Olympus Corp [TYO: 7733] [ADR: OCPNY] [GDR: OLYs] https://www.olympus-global.com

Olympus Launches THUNDERBEAT Energy Device for Open Surgery

Olympus Corporation (Olympus), a global medtech company committed to making people’s lives healthier, safer, and more fulfilling, today announced the release of the THUNDERBEAT(TM) Open Fine Jaw Type X surgical energy devices for open surgery. With a new thermal shield, the THUNDERBEAT Open Fine Jaw Type X surgical energy device is designed to support safer procedures.[i] The device is available commercially in Japan. The commercial launch of the product in Europe, the U.S., and South Korea is expected in October 2022, with continued launches in other countries and regions following.

This device is part of Olympus’ THUNDERBEAT portfolio of hybrid energy devices that deliver both ultrasonic and bipolar energy simultaneously for tissue management, including hemostatic cutting and dissection, in laparoscopic surgery and open surgery. The THUNDERBEAT hybrid devices eliminate the need for multiple instruments during the surgery, contributing to efficiency in the operating room and reduced operation time.[ii]

“This latest addition to our differentiated THUNDERBEAT line of products continues to deliver on Olympus’ commitment to offering hospitals a full portfolio of Advanced Energy devices providing best-in-class functionality for numerous procedures and specialties in minimally invasive and open surgery,” said Phil Roy, Global Vice President and General Manager of the Surgical Devices Business Unit.

The THUNDERBEAT(TM) Open Fine Jaw Type X device is designed for open surgical procedures that require delicate and fine tissue dissection, such as in thyroidectomy or radical neck dissection. The new thermal shield improves the thermal profile on the grasping surface, which reduces the risk of unintended heat damage to nearby tissue, nerves and other structures.[i] The jaw design maintains a finely curved tip for precise dissection and enhanced visibility during use.[i]

  •  New Thermal Shield Supports Safer Procedures
    The newly developed thermal shield at the distal tip slows heat transfer from the probe to the exterior surface of the jaw and reduces the risk of unintended heat damage to surrounding tissue and vessels.[i]
  • Fine Shape of Distal Tip Supports Precise Procedures
    The slim shape of the distal tip supports precise tissue management capabilities including fine dissection and firm grasping force, cutting and sealing to the tip of the device, and blunt dissection.[i]
  • Simultaneous Output of Two Energies Enables a Variety of Operations with One Device
    Delivering simultaneous bipolar and ultrasonic energy enables fast, hemostatic cutting, easy dissection, and reliable vessel sealing and division. A separate advanced bipolar[i] function enables vessel sealing and spot coagulation without cutting, when desired.

The THUNDERBEAT(TM) Open Fine Jaw Type X device is a single use hybrid ultrasonic and bipolar electrosurgical instrument intended for use in open surgery. This device should not be used for tubal sterilization or tubal coagulation for sterilization procedures. Use with caution in patients with electronic implants, such as a cardiac pacemaker, or nerve simulators, to avoid possible hazard to patients due to interference. Before use, thoroughly review the product manual and use the equipment as instructed.

The THUNDERBEAT Open Fine Jaw Type X device is manufactured by Olympus Medical Systems Corporation.

About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Starting with its early contributions to the development of the polypectomy snare, Olympus’ Therapeutic Solutions portfolio has grown to include a wide range of medical devices to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.

[i] Data on file with Olympus as of May 11, 2020
[ii] Data on file with Olympus as of June 26, 2015

Olympus to Use 100% Renewable Electricity at R&D and Manufacturing Sites in Japan

  • Leads to 70% renewable energy use on a global level and marks significant progress towards achieving net zero carbon emissions by 2030

Olympus Corporation (Olympus – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announces that from April 2022, the company has begun to exclusively source 100% of the electricity used at its major R&D and manufacturing sites in Japan from renewable sources.

As a result, CO2 emissions from Olympus Group facilities in Japan will be reduced by approximately 40,000 tons per year. The percentage of the Olympus Group’s total electricity use* in fiscal 2023 (ending March 2023) from renewable energy sources is expected to substantially increase from approximately 14% in the previous fiscal year to approximately 70%.

– Transition to Renewable Energy Usage across the Olympus Group (Facilities in Japan and Overseas)
FY2020 11.7%
FY2021 12.7%
FY2022 (estimate) 14% (approx.)
FY2023 (estimate) 70% (approx.)
*Excluding recently acquired companies, certain service offices, and certain sales offices.

Olympus has set a goal of achieving net zero CO2 emissions from its site operations by 2030, as part of its commitment to achieving environmentally responsible business growth and creating a sustainable society. This is a key goal in line with our ESG materiality targets focused on the theme of a “carbon neutral society and circular economy.”

The company has already introduced a wide range of initiatives to reduce CO2 emissions. This includes the use of 100% renewable energy at some manufacturing sites in Europe and the United States, the installation of solar power generation facilities at some manufacturing sites in Japan, and support of the recommendations made by the Task Force on Climate-related Financial Disclosures (TCFD)*.

To achieve its carbon neutral goal, Olympus will continue to optimize manufacturing processes and promote energy-saving measures, is committed to further accelerate the shift to renewable energy sources across the company, thereby contributing to the decarbonization of society on a global level.

About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 30,000 employees worldwide in nearly 40 countries and regions. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp (https://twitter.com/olympus_corp).

Olympus Contact
Communications
Contact Olympus: https://www.olympus-global.com/products/contact/

*News release “Olympus Targets Carbon Neutrality by 2030 – Adds Carbon Neutrality and Circular Economy to its ESG Materiality and Supports the Recommendations of the Task Force on Climate-Related Financial Disclosures”:
https://www.olympus-global.com/news/2021/contents/nr02125/nr02125_00001.pdf